Jett, John E. http://orcid.org/0000-0002-1940-457X
McLaughlin, Michael http://orcid.org/0000-0002-5628-1564
Lee, Mark S. http://orcid.org/0000-0001-8281-0039
Parish, Lawrence Charles http://orcid.org/0000-0002-4612-1508
DuBois, Janet http://orcid.org/0000-0002-7487-7716
Raoof, Tooraj Joseph http://orcid.org/0000-0001-8634-4303
Tabolt, Glenn http://orcid.org/0000-0002-9668-8270
Wilson, Timothy http://orcid.org/0000-0001-7085-7462
Somerville, Matthew C. http://orcid.org/0000-0001-5315-3164
DellaMaestra, Wayne http://orcid.org/0000-0002-9559-9815
Piscitelli, Stephen C. http://orcid.org/0000-0002-4528-3273
Funding for this research was provided by:
Dermavant Sciences, Inc.
Article History
Accepted: 26 September 2021
First Online: 28 October 2021
Declarations
:
: Research was funded by Dermavant Sciences, Inc.
: JEJ, WDM, MM, SCP, MCS, GT, and TW are employees of Dermavant Science, Inc. LCP is an investigator for Dermavant Science, Inc. JDB is an investigator for Allergan, Aclaris Therapeutics, Galderma USA, Brickell Biotech, Derma Therapeutics, Endo International, LEO Pharmaceuticals, Cara Therapeutics, Arcutis, Boston Pharmaceuticals, Atacama Therapeutics, Biofrontera, Bristol-Myers Squibb, RAPT Therapeutics, NFlection Therapeutics, Incyte Corporation, and Bellus Health. MSL is an investigator for Abbvie, Asana, Pfizer, Eli Lilly, AstraZeneca, Leo, Arena, Dermira, Cara, Bellus, Foamix, Arcutis, Incyte, UCB, and Boehringer Ingelheim. TJR has no conflicts of interest to disclose.
: The data that support the findings of this study are proprietary and are not publicly available. The data may be made available upon reasonable request and with permission from Dermavant after marketing approval is obtained, but restrictions will apply to the availability of these data.
: Not applicable.
: Conceptualization: GT, JEJ, LCP, MM, and SCP. Data curation: GT, JEJ, and WDM. Formal analysis: JEJ, WDM, MM, MCS, and TW. Funding acquisition: JEJ and SCP. Investigation: JDB, JEJ, LCP, MSL, SCP, and TJR. Methodology: GT, JEJ, MM, WDM, SCP, and TW. Project administration: GT, JEJ, MM, and WDM. Resources: SCP. Software: WDM. Supervision: GT, JEJ, MM, WDM, and SCP. Validation: WDM. Visualization: JEJ, MM, and SCP. Writing—original draft preparation: GT, JEJ, MM, WDM, SCP, and TW. Writing—review and editing: JEJ, WDM, MM, SCP, MCS, GT, TW, LCP, JDB, MSL, and TJR.
: This study was approved by the central Institutional Review Board, Advarra, and conducted in accordance with International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practice and all applicable subject privacy requirements, and the ethical principles that are outlined in the Declaration of Helsinki 2008.
: Written informed consent was obtained from all individual participants in the study.